Australia's CSL makes $11.7bn bid for Swiss pharma Vifor

Australian biotech group CSL has agreed a deal to acquire Swiss drugmaker Vifor Pharma in an all-cash deal that expands its speciality medicines business.

Trial sets up filings for uniQure's haemophilia gene therapy

Dutch biotech uniQure and partner CSL Behring are planning to file for approval of their gene therapy for haemophilia B, armed with new trial data that they say answers earlier concerns abo

$2bn deal sees uniQure license haemophilia B gene therapy to...

UniQure has signed a deal that could be worth over $2 billion with CSL Behring – giving the company exclusive global rights to uniQure’s gene therapy for haemophilia B. 

CSL, BrightInsight team up on digital health for rare diseas...

CSL Behring has signed a deal with US firm BrightInsight to develop digital health products to help patients with rare diseases manage their conditions.

Plasma firms join forces on “unbranded” coronavirus treatmen...

CSL accuses ex-exec, now at Pharming, of stealing trade secr...